About Abeona Therapeutics
Abeona Therapeutics Inc. is a Delaware-based clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases.
Abeona Therapeutics Inc.’s Clinical Programs: Abeona Therapeutics' lead clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa ("RDEB"), which is currently in the pivotal Phase 3 VIITAL™clinical trial. Following a comprehensive portfolio review in early 2022, the Company has decided to focus its research and development resources on the VIITAL™ readout while actively seeking a potential commercialization partner for EB-101 to reduce operating costs and extend cash runway. As part of this portfolio prioritization, the Company has intensified its efforts to form a strategic partnership to acquire the development activities for the AAV-based gene therapy ABO -102 for Sanfilippo syndrome type A ("MPS IIIA") and discontinued the development of AAV-based gene therapy ABO -101 for Sanfilippo syndrome type B ("MPS IIIB").
Abeona Therapeutics Inc. was Founded in 2015: Abeona Therapeutics Inc. was Founded in 2015 with headquarters located at New York, United States. At present, Vishwas Seshadri, Ph.D., M.B.A. serves as Chief Executive Officer and Director, Brian Kevany, Ph.D. as Vice President and Chief Technical Officer and Head of Research, and Joseph Vazzano as Chief Financial Officer.
Abeona Therapeutics Inc.’s Patient Advocacy and Community Engagements: The company supports its patient communities by advocating for them. This includes participating in special events, patient conferences and industry forums that raise awareness of the diseases the company seeks to treat, educate the public and inspire others to advocate for patients.
Abeona Therapeutics Inc.’s Mission: Working together to deliver cell and gene therapies for people impacted by serious diseases. Our strategy to harness the promise of genetic medicine to transform the lives of patients is inspired by our vision, to realize a world where cure is the new standard of care.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Abeona Therapeutics
|StreetAddress: 1330 Avenue of the Americas Fl 33, AddressLocality: New York City, AddressRegion: New York, PostalCode: 10019, AddressCountry: United States
|Number Of Employees
New York City, US
23 Feb 2024